Qualigen Therapeutics, Inc.
QLGN
$3.11
$0.103.32%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -91.44% | -35.78% | -71.57% | 51.11% | 54.93% |
| Gross Profit | 91.44% | 35.78% | 71.57% | -51.11% | -54.93% |
| SG&A Expenses | -14.33% | -59.35% | -22.76% | -62.52% | -47.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.34% | -51.67% | -46.37% | -33.83% | -19.93% |
| Operating Income | 54.34% | 51.67% | 46.37% | 33.83% | 19.93% |
| Income Before Tax | 44.47% | 58.18% | 37.19% | 31.30% | -2.89% |
| Income Tax Expenses | -- | -130.00% | 28.57% | -1,300.00% | -- |
| Earnings from Continuing Operations | 44.54% | 58.26% | 37.16% | 31.44% | -2.89% |
| Earnings from Discontinued Operations | -- | -236.61% | -- | 100.62% | 38.11% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.93% | 54.49% | 47.15% | 61.55% | 4.41% |
| EBIT | 54.34% | 51.67% | 46.37% | 33.83% | 19.93% |
| EBITDA | 53.31% | 50.83% | 45.20% | 33.80% | 21.01% |
| EPS Basic | 87.02% | 69.76% | 54.60% | 68.98% | 25.37% |
| Normalized Basic EPS | 82.84% | 71.79% | 40.98% | 58.61% | 20.21% |
| EPS Diluted | 87.02% | 69.76% | 54.60% | 68.97% | 25.37% |
| Normalized Diluted EPS | 82.84% | 71.79% | 40.98% | 58.61% | 20.21% |
| Average Basic Shares Outstanding | 284.06% | 50.59% | 19.86% | 23.96% | 28.01% |
| Average Diluted Shares Outstanding | 284.06% | 50.59% | 19.86% | 23.96% | 28.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
